Cargando…
The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan
BACKGROUND: Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19 patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19 patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190739/ https://www.ncbi.nlm.nih.gov/pubmed/34112103 http://dx.doi.org/10.1186/s12877-021-02310-x |
_version_ | 1783705744149839872 |
---|---|
author | Ma, Yao He, Min Hou, Li-Sha Xu, Shen Huang, Zhi-Xin Zhao, Na Kang, Yan Yue, Ji-Rong Wu, Chenkai |
author_facet | Ma, Yao He, Min Hou, Li-Sha Xu, Shen Huang, Zhi-Xin Zhao, Na Kang, Yan Yue, Ji-Rong Wu, Chenkai |
author_sort | Ma, Yao |
collection | PubMed |
description | BACKGROUND: Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19 patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19 patients. The aim of our prospective cohort study is to investigate the association between sarcopenia risk and severe disease among COVID-19 patients aged ≥60 years. METHOD: A prospective cohort study of 114 hospitalized older patients (≥60 years) with confirmed COVID-19 pneumonia between 7 February, 2020 and 6 April, 2020. Epidemiological, socio-demographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for sarcopenia on admission using the SARC-F scale and the outcome was the development of the severe disease within 60 days. We used the Cox proportional hazards model to identify the association between sarcopenia and progression of disease defined as severe cases in a total of 2908 person-days. RESULT: Of 114 patients (mean age 69.52 ± 7.25 years, 50% woman), 38 (33%) had a high risk of sarcopenia while 76 (67%) did not. We found that 43 (38%) patients progressed to severe cases. COVID-19 patients with higher risk sarcopenia were more likely to develop severe disease than those without (68% versus 22%, p < 0.001). After adjustment for demographic and clinical factors, higher risk sarcopenia was associated with a higher hazard of severe condition [hazard ratio = 2.87 (95% CI, 1.33–6.16)]. CONCLUSION: We found that COVID-19 patients with higher sarcopenia risk were more likely to develop severe condition. A clinician-friendly assessment of sarcopenia could help in early warning of older patients at high-risk with severe COVID-19 pneumonia. |
format | Online Article Text |
id | pubmed-8190739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81907392021-06-10 The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan Ma, Yao He, Min Hou, Li-Sha Xu, Shen Huang, Zhi-Xin Zhao, Na Kang, Yan Yue, Ji-Rong Wu, Chenkai BMC Geriatr Research BACKGROUND: Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19 patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19 patients. The aim of our prospective cohort study is to investigate the association between sarcopenia risk and severe disease among COVID-19 patients aged ≥60 years. METHOD: A prospective cohort study of 114 hospitalized older patients (≥60 years) with confirmed COVID-19 pneumonia between 7 February, 2020 and 6 April, 2020. Epidemiological, socio-demographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for sarcopenia on admission using the SARC-F scale and the outcome was the development of the severe disease within 60 days. We used the Cox proportional hazards model to identify the association between sarcopenia and progression of disease defined as severe cases in a total of 2908 person-days. RESULT: Of 114 patients (mean age 69.52 ± 7.25 years, 50% woman), 38 (33%) had a high risk of sarcopenia while 76 (67%) did not. We found that 43 (38%) patients progressed to severe cases. COVID-19 patients with higher risk sarcopenia were more likely to develop severe disease than those without (68% versus 22%, p < 0.001). After adjustment for demographic and clinical factors, higher risk sarcopenia was associated with a higher hazard of severe condition [hazard ratio = 2.87 (95% CI, 1.33–6.16)]. CONCLUSION: We found that COVID-19 patients with higher sarcopenia risk were more likely to develop severe condition. A clinician-friendly assessment of sarcopenia could help in early warning of older patients at high-risk with severe COVID-19 pneumonia. BioMed Central 2021-06-10 /pmc/articles/PMC8190739/ /pubmed/34112103 http://dx.doi.org/10.1186/s12877-021-02310-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ma, Yao He, Min Hou, Li-Sha Xu, Shen Huang, Zhi-Xin Zhao, Na Kang, Yan Yue, Ji-Rong Wu, Chenkai The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title | The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title_full | The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title_fullStr | The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title_full_unstemmed | The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title_short | The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan |
title_sort | role of sarc-f scale in predicting progression risk of covid-19 in elderly patients: a prospective cohort study in wuhan |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190739/ https://www.ncbi.nlm.nih.gov/pubmed/34112103 http://dx.doi.org/10.1186/s12877-021-02310-x |
work_keys_str_mv | AT mayao theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT hemin theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT houlisha theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT xushen theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT huangzhixin theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT zhaona theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT kangyan theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT yuejirong theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT wuchenkai theroleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT mayao roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT hemin roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT houlisha roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT xushen roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT huangzhixin roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT zhaona roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT kangyan roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT yuejirong roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan AT wuchenkai roleofsarcfscaleinpredictingprogressionriskofcovid19inelderlypatientsaprospectivecohortstudyinwuhan |